CE Holdings (4320) Q4 2025 earnings summary

Executive summary

• Achieved record highs in revenue, operating income, and net income for the fiscal year ended September 2025, driven by strong sales and maintenance of electronic medical record (EMR) systems.

• Net sales increased by 8.8% year-over-year to ¥15,831 million for the year ended September 30, 2025.

• Operating income rose 22.9% to ¥1,411 million; ordinary income up 23.6% to ¥1,426 million.

• Net income attributable to parent company shareholders jumped 1162.2% to ¥1,557 million, reflecting one-time gains.

• Comprehensive income attributable to owners of parent reached ¥1,573 million, up from ¥121 million the previous year.

Financial highlights

• Gross profit increased to ¥3,581 million from ¥3,365 million year-over-year.

• Total assets rose to ¥12,746 million from ¥11,251 million, and net assets increased to ¥8,842 million from ¥6,599 million.

• Cash and cash equivalents at year-end were ¥5,032 million, up from ¥3,826 million.

• Cash flows from operating activities improved to ¥986 million from ¥752 million year-over-year.

• Special gains included ¥873 million from sale of Micron shares; impairment losses and goodwill amortization were reduced.

Outlook and guidance

• For FY2026, revenue is forecast at ¥15,000 million, with operating income at ¥1,500 million and net income at ¥870 million, excluding Micron-related effects.

• For the year ending September 30, 2026, net sales are forecast at ¥15,000 million, a 5.3% decrease year-over-year.

• Operating profit is projected at ¥1,020 million, down 17.1% year-over-year, and profit attributable to owners of parent is expected to decline 44.2% to ¥870 million.

• Earnings per share forecast for the full year is ¥52.28.

• Excluding one-time items, all major profit metrics are expected to reach record levels.